Jupiter Neurosciences (JUNS) Other Non Operating Income (2023 - 2024)
Jupiter Neurosciences (JUNS) posted quarterly Other Non Operating Income of -$1.0 million for Q4 2024, down 211.26% year-over-year from $903404.0 in Q1 2024, and down 10268.18% quarter-over-quarter from $9885.0 in Q3 2024.
Jupiter Neurosciences (JUNS) Other Non Operating Income (2023 - 2024) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Other Non Operating Income for 2 consecutive years, with -$1.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Other Non Operating Income fell 211.26% year-over-year to -$1.0 million; the TTM figure through Dec 2024 stood at -$1.1 million (changed N/A YoY), while the FY2025 annual figure was $281932.0, up 629.38% from the prior year.
- Other Non Operating Income retreated to -$1.0 million in Q4 2024 per JUNS's latest filing, from $9885.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $903404.0 in Q4 2023 and bottomed at -$1.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | 9,885.00 |
| Jun 30, 2024 | -25,431.00 |
| Mar 31, 2024 | -37,711.00 |
| Dec 31, 2023 | 903,404.00 |
| Sep 30, 2023 | -34,086.00 |